GT Biopharma
GTBP
38 hedge funds and large institutions have $374K invested in GT Biopharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
81% more funds holding
Funds holding: 21 → 38 (+17)
68% more capital invested
Capital invested by funds: $222K → $374K (+$152K)
5.98% less ownership
Funds ownership: 10.52% → 4.54% (-6%)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$38.9K |
| 2 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$35.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$29.2K |
| 4 |
Jane Street
New York
|
+$18.5K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$83.5K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$58K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.25K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.34K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$3.22K |
GTBP Hedge Fund Activity: Q4 2025 in Review
38 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2025, worth a combined $374K — up 68% from $222K a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GTBP positions and 5 closed out — a net gain of 17 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Scientech Research LLC, opening a new position worth an estimated $38.9K. The largest seller was DRW Securities, exiting entirely with an estimated $83.5K sold.
- 38 institutional investors held GT Biopharma (GTBP) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $374K of GT Biopharma stock for Q4 2025, up 68% quarter-over-quarter.
- 22 funds opened new GT Biopharma positions in Q4 2025 and 5 closed out, a net change of +17 holders.
- The largest GT Biopharma buyer in Q4 2025 was Scientech Research LLC, an estimated $38.9K added.
- The largest GT Biopharma seller in Q4 2025 was DRW Securities, an estimated $83.5K sold.
Based on aggregated 13F filings for Q4 2025.